COVID-associated pulmonary aspergillosis and azole resistance Aspergillus species; a laboratory-based study from Pakistan
DOI:
https://doi.org/10.61529/idjp.v34i4.432Abstract
Background: COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a significant complication in critically ill patients, leading to increased morbidity and mortality, particularly when diagnosis is delayed or antifungal resistance is present. A previous study from our centre reported a CAPA incidence of 21.7% with high associated mortality. This study aimed to evaluate azole resistance in Aspergillus species isolated from COVID-19 patients using a standardized screening approach.
Materials and Methods: This study included Aspergillus isolates recovered from respiratory specimens of COVID-19 patients admitted to Aga Khan University Hospital, Karachi, between July 2020 and January 2022. Azole resistance screening was performed using the CDC agar-based methodology with itraconazole, voriconazole, and posaconazole. Isolates that demonstrated growth in any azole-containing well were further tested for minimum inhibitory concentrations (MICs) using broth microdilution. Quality control strains included Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, and A. flavus ATCC 204304.
Results: A total of 174 Aspergillus isolates (A. flavus 85, A. niger 41, A. fumigatus 36, A. terreus 8, A. nidulans 3, A. versicolor 1) from 125 patients (40 CAPA; 85 colonization) were analysed. Growth was observed on voriconazole screening agar in 24 (13.7%) isolates. No growth was seen in the itraconazole or posaconazole wells. MIC testing of 18 voriconazole-screened isolates confirmed that all were azole-susceptible.
Conclusion: Although initial screening suggested possible azole resistance, none were confirmed resistant by MIC testing. These findings highlight the need for continued surveillance to monitor emerging resistance in Aspergillus species in Pakistan.
Keywords: Azole resistance, CAPA, COVID-19
References
Dewi IMW, Janssen NAF, Rosati D, Bruno M, Netea MG, Brüggemann RJM, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis. Curr Opin Microbiol. 2021; 62: 21-7. DOI: https://doi.org/10.1016/j.mib.2021.04.006
Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022; 7(8): 1127-40. DOI: https://doi.org/10.1038/s41564-022-01172-2
Mitaka H, Kuno T, Takagi H, Patrawalla P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses. 2021; 64(9): 993-1001. DOI: https://doi.org/10.1111/myc.13292
Feys S, Lagrou K, Lauwers HM, Haenen K, Jacobs C, Brusselmans M, et al. High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation. Clin Infect Dis. 2023; 78(2): 361-70. DOI: https://doi.org/10.1093/cid/ciad546
Gioia F, Walti LN, Orchanian-Cheff A, Husain S. Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Lancet Respir Med. 2024; 12(3): 207-16. DOI: https://doi.org/10.1016/s2213-2600(23)00408-3
Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF. Azole-Resistant COVID-19-Associated pulmonary aspergillosis in an immunocompetent host: A case report. J Fungi. 2020; 6(2): 79. DOI: https://doi.org/10.3390/jof6020079
Ghelfenstein-Ferreira T, Saade A, Alanio A, Bretagne S, Araujo de Castro R, Hamane S, et al. Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU – A case report. Med Mycol Case Rep. 2021; 31: 15-8. DOI: https://doi.org/10.1016/j.mmcr.2020.06.006
Mohamed A, Hassan T, Trzos-Grzybowska M, Thomas J, Quinn A, O'Sullivan M, et al. Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination. Med Mycol Case Rep. 2021; 31: 11-4. DOI: https://doi.org/10.1016/j.mmcr.2020.06.005
Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021; 21(6): e149-e62. DOI: https://doi.org/10.1016/s1473-3099(20)30847-1
Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020; 63(8): 766-70. DOI: https://doi.org/10.1111/myc.13135
Nasir N, Farooqi J, Zubair SM, Ayub M, Khan S, Wiqar MH, et al. Comparison of risk factors and outcome of patients with and without COVID-19-associated pulmonary aspergillosis from Pakistan: A case-control study. Mycoses. 2023;66(1):69-74. DOI: https://doi.org/10.1111/myc.13529
Mortensen Klaus L, Mellado E, Lass-Flörl C, Rodriguez-Tudela Juan L, Johansen Helle K, Arendrup Maiken C. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010; 54(11): 4545-9. DOI: https://doi.org/10.1128/aac.00692-10
John HR. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. Second edition. M38-A2. Clin Lab Stand Inst. 2008; 28(16): 1-35. Available from: http://www.njccwei.com/uploadfiles/2024/01/20240103142342341.pdf
Wayne PA. Epidemiological cuttoff values for antifungal susceptibility testing. 3rd ed. CLSI supplement M59. 2020.
Simmons BC, Rhodes J, Rogers TR, Verweij PE, Abdolrasouli A, Schelenz S, et al. Genomic epidemiology identifies azole resistance due to TR34/ L98H in European Aspergillus fumigatus causing COVID-19-associated pulmonary aspergillosis. J Fungi. 2023; 9(11): 1104. DOI: https://doi.org/10.3390/jof9111104
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017; 3(4): 57. DOI: https://doi.org/10.3390/jof3040057
Lestrade PPA, Buil JB, van der Beek MT, Kuijper EJ, van Dijk K, Kampinga GA, et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018. Emerg Infect Dis. 2020; 26(7): 1447-55. DOI: https://doi.org/10.3201/eid2607.200088
Chong GM, van der Beek MT, von dem Borne PA, Boelens J, Steel E, Kampinga GA, et al. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: A multicentre validation of the AsperGenius assay® in 201 patients with haematological disease suspected for invasive aspergillosis. J Antimicrob Chemother. 2016; 71(12): 3528-35. DOI: https://doi.org/10.1093/jac/dkw323
Habibzadeh A, Lankarani KB, Farjam M, Akbari M, Kashani SMA, Karimimoghadam Z, et al. Prevalence of fungal drug resistance in COVID-19 infection: A global meta-analysis. Curr Fungal Infect Rep. 2022; 16(4): 154-64. DOI: https://doi.org/10.1007/s12281-022-00439-9
Chang Y-H, Liu T-H, Wu J-Y, Lai C-C. The association between corticosteroids and aspergillosis among COVID-19 patients. J Infect. 2023; 86(4): 394-6. DOI: https://doi.org/10.1016/j.jinf.2023.01.034
Salmanton-García J, Sprute R, Stemler J, Bartoletti M, Dupont D, Valerio M, et al. COVID-19-associated pulmonary aspergillosis, March-August 2020. Emerg Infect Dis. 2021;27(4):1077-86. DOI: https://doi.org/10.3201/eid2704.204895
van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020; 202(1): 132-5. DOI: https://doi.org/10.1164/rccm.202004-1038le
Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020; 8(6): e48-e9. DOI: https://doi.org/10.1016/s2213-2600(20)30237-x
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020; 63(6): 528-34. DOI: https://doi.org/10.1111/myc.13096
Erami M, Hashemi SJ, Raiesi O, Fattahi M, Getso MI, Momen-Heravi M, et al. COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection. 2023; 51(1): 223-30.
DOI: https://doi.org/10.1007/s15010-022-01907-7
Meijer EFJ, Dofferhoff ASM, Hoiting O, Meis JF. COVID-19-associated pulmonary aspergillosis: A prospective single-center dual case series. Mycoses. 2021; 64(4): 457-64. DOI: https://doi.org/10.1111/myc.13254
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 sadaf zaka, mehreen shahid, joveria farooqi, Tooba raheem, Muhammad faheem naqvi, kauser jabeen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
